Cytek Biosciences, Inc. (CTKB)

Over the past six months, Cytek Biosciences' stock price has been impacted by several events. The company announced preliminary unaudited revenue for 2025 and Q4 2025, reporting an 8% growth compared to Q4 2024. Q3 2025 revenue increased by 2% year-over-year, but the company posted an EPS loss. Analysts have issued price targets for CTKB, with a median target of $6.25 and a consensus rating of "Hold". Institutional investors have adjusted their positions in CTKB shares. Cytek Biosciences' Board of Directors authorized a stock repurchase plan of up to $50 million. The share price declined by 27.54% from January 6, 2025, to January 2, 2026.

Based on the available information, there is no explicit mention of significant demand seasonality for Cytek Biosciences' products and services. The company has reported continued global demand growth for its products and strong growth in Services, Reagents and Asia Pacific instrument revenue and an improvement in instrument revenue growth in the US and EMEA in the fourth quarter of 2025. The growth in recurring revenue from services and reagents also suggests a relatively stable demand for these aspects of their business.

Cytek Biosciences, Inc. (CTKB) is a cell analysis solutions company focused on advancing cell analysis tools through its patented Full Spectrum Profiling (FSP) technology. The company's FSP platform aims to provide high-resolution, high-content, and high-sensitivity cell analysis. Its major products and services include core FSP instruments like the Cytek Aurora and Northern Lights systems, the Cytek Aurora CS cell sorter, the Cytek Orion reagent cocktail preparation system, flow cytometer and imaging products under the Amnis and Guava brands, reagents, software, and services, enhanced small particle (ESP) detection technology, the Cytek Aurora Evo, and the Cytek Muse Micro cell analyzer. Cytek's instruments are utilized in various fields such as infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery.

Cytek Biosciences has a significant global presence with offices and distribution channels across North America, Europe, China, and the Asia-Pacific regions, serving nearly 2,000 customers in over 70 countries. While the majority of its revenue is generated from the United States, Cytek has been actively expanding its international operations, including relocating its European headquarters to Amsterdam and opening a new manufacturing facility in Singapore.

In the past year, Cytek Biosciences was included on TIME's 2026 list of America's Growth Leaders. The Cytek Muse Micro cell analyzer won the BioTech Breakthrough Award for Drug Discovery Solution of the Year. Cytek Biosciences announced its commitment to expanding access to flow cytometry. The company expanded its European presence with a new facility in Amsterdam. Cytek Biosciences launched the Cytek Aurora Evo system. The company expanded its cell analysis offerings with the affordable and user-friendly Cytek Muse Micro System. Cytek's Northern Lights CLC system and certain reagents are approved for clinical use in China and the European Union.

Cytek Biosciences, Inc. (CTKB) is primarily owned by institutional shareholders, who hold 62.59% of the stock, followed by Cytek Biosciences insiders at 22.32%, and retail investors at 15.09%. Major institutional owners include BlackRock, Inc., Topline Capital Management, LLC, and Vanguard Group Inc. Ra Capital Management LP is the largest individual shareholder, owning 10.46% of the company.